Aclaris Therapeutics, Inc. (ACRS)
ACRSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$4.24
+0.3400 (+8.72%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $672.52m
- P/E
- –
- EPS, last 4 quarters
- $-0.5800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.10 to $6.60
- Average volume
- 3.16m
- Previous close
- $3.90
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $11.50, +171.2% from here
Earnings
next estimate $-0.1600Next report
Dec 2025
-6.7%
Mar 2026
+6.3%
Jun 2026
+6.3%
Sep 2026
+25.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.30m | $1.29m | $2.00m | $1.63m |
| Gross profit | $2.76m | $763.0k | $1.60m | $1.41m |
| Operating income | -$17.15m | -$22.73m | -$22.19m | -$24.24m |
| Net income | -$14.61m | -$19.80m | -$19.82m | -$21.50m |
Last four quarters: revenue $8.22m, margin -921.5%, free cash flow -$62.18m
News
8 latest- Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?Zacks · 4 days ago
- Aclaris Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- Aclaris Therapeutics, Inc. Enters Underwriting Agreement for Offering of 7,785,714 Shares of Common Stock and 6,500,000 Pre-Funded WarrantsFintel · Oct 27, 2026
- Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1bMarketBeat · Oct 27, 2026
- Aclaris Therapeutics, Inc. Announces Phase 1b Results for ATI-052 and Estimates $204.6 million in CashFintel · Oct 27, 2026
- Aclaris Reports Positive Phase 1b Results For ATI-052 In Atopic Dermatitis And Asthma; Stock Down RTTNews · Oct 27, 2026
- Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?Zacks · Oct 21, 2026
The company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- aclaristx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.